Joe Horn, president of Global Therapeutics, Ever since the issue of late-stage thrombosis associated with drug-eluting coronary stents (DECS) came to light recently, interventional cardiologists have been reexamining the valuable role bare metal stents can play in treating coronary artery disease in many patients. Not only do our bare metal stents eliminate the concerns associated with potential delayed reactions from DES in certain coronary patients, our bare metal cobalt chromium stent has advanced features designed to improve clinical performance of BMS in coronary arteries. The GTX stent has been engineered specifically to eliminate the technical challenges, such as recoil, stent balloon retention and stent spring-back, that have been associated with earlier cobalt chromium stent designs currently on the market
GTX offers a significant cost-savings. Bare metal versions of coronary stents historically cost about one-third as much as their drug-coated iterations, making bare metal stents a more cost-effective option in treating many coronary disease patients. GTX platform offers a significant advance in bare metal stent technology many cardiologists and hospitals will welcome both for its potential clinical benefits and for its cost-effectiveness.”
Global Therapeutics also developing a breakthrough drug-eluting stent (DES) technology using the GTX platform and an improved application of antisense gene therapy—developed by its partner, AVI BioPharma, Inc.
